Meeting
2021 ASCO Annual Meeting
Doublet (FOLFOX or FOLFIRI) versus triplet (FOLFOXIRI) backbone chemotherapy regimen as first-line treatment of metastatic colorectal cancer: A meta-analysis and systematic review.
Authors
Vishal Jindal
Beaumont Health, Department of Hematology and Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, MI
Vishal Jindal , Ruby Gupta , Kamal Kant Sahu , Mandeep Singh Rahi , Michael J. Stender , Ishmael A. Jaiyesimi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3593)
DOI
10.1200/JCO.2021.39.15_suppl.3593
Abstract #
3593
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
First Author: Kentaro Yamazaki
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).
First Author: Karam Ashouri
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Predictive factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer.
First Author: AhReum Lim